Relay Therapeutics (RLAY) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation, BTD, to zovegalisib in combination with fulvestrant for the treatment of adults with PIK3CA mutant, hormone receptor positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RLAY:
- Relay Therapeutics upgraded at Oppenheimer ahead of VIKTORIA-1 readout
- Relay Therapeutics upgraded to Outperform from Perform at Oppenheimer
- Private Markets: SpaceX interviews banks to lead IPO, Skild AI raises $1.4B
- Relay Therapeutics announces analysis of data for zovegalisib
- Relay Therapeutics upgraded to Overweight from Equal Weight at Wells Fargo